[
  {
    "ts": "2025-12-18T19:15:46+00:00",
    "headline": "Moderna (MRNA) Valuation Check as CEPI Backs Phase 3 H5 Bird Flu Vaccine with $54.3 Million Funding",
    "summary": "Moderna (MRNA) is back in the spotlight after securing up to $54.3 million from CEPI to help fund a Phase 3 trial of its H5 bird flu vaccine candidate, mRNA-1018. See our latest analysis for Moderna. The CEPI funding has helped extend a short burst of momentum, with Moderna’s 1 month share price return of 23.22 percent contrasting sharply with a 1 year total shareholder return of negative 20.46 percent. This suggests sentiment is improving, but the longer term recovery story is still being...",
    "url": "https://finance.yahoo.com/news/moderna-mrna-valuation-check-cepi-191546899.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ca9d7013-fb5a-3455-98f9-7d13cf1a18f7",
      "content": {
        "id": "ca9d7013-fb5a-3455-98f9-7d13cf1a18f7",
        "contentType": "STORY",
        "title": "Moderna (MRNA) Valuation Check as CEPI Backs Phase 3 H5 Bird Flu Vaccine with $54.3 Million Funding",
        "description": "",
        "summary": "Moderna (MRNA) is back in the spotlight after securing up to $54.3 million from CEPI to help fund a Phase 3 trial of its H5 bird flu vaccine candidate, mRNA-1018. See our latest analysis for Moderna. The CEPI funding has helped extend a short burst of momentum, with Moderna’s 1 month share price return of 23.22 percent contrasting sharply with a 1 year total shareholder return of negative 20.46 percent. This suggests sentiment is improving, but the longer term recovery story is still being...",
        "pubDate": "2025-12-18T19:15:46Z",
        "displayTime": "2025-12-18T19:15:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lV6Oo0M_C3X63uXoBkpnwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KdbFtaQiMRVA6Enl712wNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-valuation-check-cepi-191546899.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-valuation-check-cepi-191546899.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-18T18:14:13+00:00",
    "headline": "Moderna, Inc. (MRNA): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Moderna, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on MRNA. Moderna, Inc.’s share was trading at $29.92 as of December 15th. MRNA’s trailing P/E was 7.06 according to Yahoo Finance. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. MRNA’s strategy from 2025–2030 emphasizes capital efficiency […]",
    "url": "https://finance.yahoo.com/news/moderna-inc-mrna-bull-case-181413478.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "88e6256d-92b7-35a6-821a-18a6ead37a71",
      "content": {
        "id": "88e6256d-92b7-35a6-821a-18a6ead37a71",
        "contentType": "STORY",
        "title": "Moderna, Inc. (MRNA): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Moderna, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on MRNA. Moderna, Inc.’s share was trading at $29.92 as of December 15th. MRNA’s trailing P/E was 7.06 according to Yahoo Finance. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. MRNA’s strategy from 2025–2030 emphasizes capital efficiency […]",
        "pubDate": "2025-12-18T18:14:13Z",
        "displayTime": "2025-12-18T18:14:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/9b4b20b7b14be2cd49d3fdf62c5391f5",
          "originalWidth": 640,
          "originalHeight": 427,
          "caption": "Is Ultragenyx Pharmaceutical Inc. (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ghgTiRhTa_WaiMtKQjkoDQ--~B/aD00Mjc7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/9b4b20b7b14be2cd49d3fdf62c5391f5.cf.webp",
              "width": 640,
              "height": 427,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NFZ2L0n6k7Ey7gSPo9HYdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/9b4b20b7b14be2cd49d3fdf62c5391f5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-inc-mrna-bull-case-181413478.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-inc-mrna-bull-case-181413478.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-18T17:32:34+00:00",
    "headline": "Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullback",
    "summary": "With federal funding cut, Moderna finds new backers for its pandemic play--just as mRNA faces a critical test",
    "url": "https://finance.yahoo.com/news/modernas-54m-lifeline-bird-flu-173234868.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "8cd6c76f-65b0-30b0-a607-841db8a40543",
      "content": {
        "id": "8cd6c76f-65b0-30b0-a607-841db8a40543",
        "contentType": "STORY",
        "title": "Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullback",
        "description": "",
        "summary": "With federal funding cut, Moderna finds new backers for its pandemic play--just as mRNA faces a critical test",
        "pubDate": "2025-12-18T17:32:34Z",
        "displayTime": "2025-12-18T17:32:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/affd672c7e3b6b05023e1a8ef798291a",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/edKKLjfF5qysqWEgzE6Gzg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/affd672c7e3b6b05023e1a8ef798291a.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0wvZ8t2uImk183ovELOTbQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/affd672c7e3b6b05023e1a8ef798291a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/modernas-54m-lifeline-bird-flu-173234868.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/modernas-54m-lifeline-bird-flu-173234868.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-18T16:51:47+00:00",
    "headline": "Why Moderna (MRNA) Stock Is Up Today",
    "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced it would receive up to $54.3 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a late-stage trial for its experimental bird flu vaccine.",
    "url": "https://finance.yahoo.com/news/why-moderna-mrna-stock-today-165147147.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "8a575797-38a2-3bf4-b97d-7b24b98ba9bd",
      "content": {
        "id": "8a575797-38a2-3bf4-b97d-7b24b98ba9bd",
        "contentType": "STORY",
        "title": "Why Moderna (MRNA) Stock Is Up Today",
        "description": "",
        "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced it would receive up to $54.3 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a late-stage trial for its experimental bird flu vaccine.",
        "pubDate": "2025-12-18T16:51:47Z",
        "displayTime": "2025-12-18T16:51:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/7ed68d581c33e574792b9fa0fe3f670c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "MRNA Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xFZGGzZnWM6N6sCUARtq9w--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/7ed68d581c33e574792b9fa0fe3f670c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aiku5oDkVhvbobAoAonIcg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/7ed68d581c33e574792b9fa0fe3f670c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-moderna-mrna-stock-today-165147147.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-moderna-mrna-stock-today-165147147.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-18T14:54:00+00:00",
    "headline": "Moderna gets funding for H5 pandemic influenza vaccine",
    "summary": "The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government funding.",
    "url": "https://www.biopharmadive.com/news/moderna-funding-h5-pandemic-avian-influenza-vaccine/808289/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "8c26e78e-9556-357f-b409-28e969b5da3f",
      "content": {
        "id": "8c26e78e-9556-357f-b409-28e969b5da3f",
        "contentType": "STORY",
        "title": "Moderna gets funding for H5 pandemic influenza vaccine",
        "description": "",
        "summary": "The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government funding.",
        "pubDate": "2025-12-18T14:54:00Z",
        "displayTime": "2025-12-18T14:54:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/ab17b0a3580390f16f2a51ea8e46db6b",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pA2Y6VcWA4VtkFQngSgsZg--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/ab17b0a3580390f16f2a51ea8e46db6b.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Dy8wPKS7DCerxa5Hc7v_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/ab17b0a3580390f16f2a51ea8e46db6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/moderna-funding-h5-pandemic-avian-influenza-vaccine/808289/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-gets-funding-h5-pandemic-145400714.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-18T12:00:00+00:00",
    "headline": "CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate",
    "summary": "Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threat If licensed and in the event of an influenza ...",
    "url": "https://finance.yahoo.com/news/cepi-fund-pivotal-phase-3-120000810.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "931a5c6f-552f-3005-add2-ddb7d06d14bc",
      "content": {
        "id": "931a5c6f-552f-3005-add2-ddb7d06d14bc",
        "contentType": "STORY",
        "title": "CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate",
        "description": "",
        "summary": "Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threat If licensed and in the event of an influenza ...",
        "pubDate": "2025-12-18T12:00:00Z",
        "displayTime": "2025-12-18T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "<![CDATA[Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership ...]]>",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y14NrymWnVHtLPxT5mPm5g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dSewxxG3XkMHQTa3gmVr6w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cepi-fund-pivotal-phase-3-120000810.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cepi-fund-pivotal-phase-3-120000810.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]